Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer
Status:
Terminated
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
Ipilimumab, an antibody that blocks cytotoxic T-lymphocyte antigen 4, and GVAX have
demonstrated anti-tumor activity in prostate cancer. Pre-clinical studies with this
combination have demonstrated potent synergy. The purpose of this study is to investigate,
using a phase-I 3+3 dose escalation design followed by an expansion cohort, the safety and
efficacy of combined treatment with GVAX and ipilimumab in castration-resistant metastatic
prostate cancer (CRPC) patients.